Human Growth Peptides Tesamorelin For Weight Loss CAS 218949-48-5
Quick Details for Tesamorelin
Product Name : Tesamorelin
Alias : Egrifta
Cas No. : 218949-48-5
Molecular Formula : C221H366N72O67S
Molecular Weight : 5135.9
Purity (HPLC) : 98.0%min.
Appearance : White Powder
Single Impurity (HPLC) : 1.0%max
Amino Acid Composition : ±10% of theoretical
Peptide Content (N%) : >80.0%(by %N)
Water Content (Karl Fischer) : <8.0%
Mass Balance : 95.0~105.0%
Grade : Pharmaceutical Grade
Storage : Reconstitute in ddH2O. Store at -20° C. Product is stable for at least 2 months.
Tesamorelin, (formerly known as TH9507), is a type of peptide called a hormone-releasing factor (GHRF). GHRF causes hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy. Tesamorelin (formerly known as TH9507) is a synthetic growth hormone-releasing factor that stimulates the pituitary gland in the brain to secrete hormone; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC,. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual). Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.
The usage for fat loss
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes HGH production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).